Close up picture of microscope in the laboratory
Our Work

Latham & Watkins Advises on Abcam’s US$5.7 Billion Sale to Danaher

August 28, 2023
Cross-border team represents longstanding client and global life science company in the transaction.

Latham & Watkins has advised Abcam plc (Nasdaq: ABCM), a global leader in the supply of life science research tools, on a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) will acquire all of the outstanding shares of Abcam for US$24 per share in cash (the ‘Transaction’), with a total enterprise value of approximately US$5.7 billion including assumed indebtedness and net of acquired cash.

The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors.

Latham has previously advised Abcam on its listing on NASDAQ, de-listing from AIM, strategic M&A activities, and a recent activist campaign.

The Latham team was led by London corporate partners Robbie McLaren, Richard Butterwick, Anna Ngo, and Jennifer Gascoyne, with associates Chris Ramsey, Aimee Godfrey, Aeneas Nalbantis, and Will Temple-Smith. Advice on US corporate matters was provided by Orange County partner Scott Shean and New York partner Leah Sauter; on executive compensation, employment & benefits matters by London partner Sarah Gadd and Washington, D.C. partner Nikhil Kumar; and on antitrust and regulatory matters by Brussels partner Héctor Armengod and counsel Philipp Studt, and Washington, D.C. partner Mandy Reeves.